Genetic Technologies Limited

GTG

Genetic Technologies Ltd. operates as a molecular diagnostics company, which engages in the provision of molecular risk assessment tests for cancer. The company is headquartered in Melbourne, Victoria and currently employs 58 full-time employees. The firm is engaged in providing genomics-based tests on health, wellness and serious disease through its geneType and EasyDNA brands. The firm offers cancer predictive testing and assessment tools to help physicians to improve health outcomes for people around the world. The firm has a proprietary risk stratification platform that integrates clinical and genetic risk to deliver outcomes to physicians and individuals. The firm operates through three segments: EasyDNA, AffinityDNA, and GeneType / Corporate. EasyDNA segment relates to EasyDNA branded test sales and expenses. AffinityDNA segment relates to AffinityDNA branded test sales and expenses. GeneType / Corporate segment relates to geneType branded test sales and expenses, including corporate charges. The GeneType test is for breast cancer, colorectal cancer, ovarian cancer, prostate cancer, coronary artery disease and mor

Vanguard US Total Market Shares Index ETF

VTS

VTS.AX was created on 2009-05-12 by Vanguard. The fund's investment portfolio concentrates primarily on total market equity. Vanguard U.S. Total Market Shares Index ETF seeks to track the performance of the CRSP US Total Market Index, providing investors with exposure to a broadly diversified collection of securities that, in the aggregate, approximates the full index in terms of key characteristics.

Vanguard MSCI Index International Shares ETF

VGS

VGS.AX was created on 2014-11-18 by Vanguard. The fund's investment portfolio concentrates primarily on total market equity. Vanguard MSCI International Shares Index ETF seeks to track the return of the MSCI World ex-Australia Index (with net dividends reinvested) in Australian dollars before taking into account fees, expenses and tax.

Australian Foundation Investment Company Limited

AFI

Australian Foundation Investment Company Ltd is a AU-based company operating in industry. The company is headquartered in Melbourne, Victoria. Australian Foundation Investment Company Limited is an investment company, which is focused on investing in Australian and New Zealand equities. Its investment objective is to pay a stable to growing dividend over time and to provide attractive total returns over the medium to long term. The company has two portfolios of securities: the investment portfolio and the trading portfolio. The investment portfolio holds securities which the Company intends to retain on a long-term basis and includes a small sub-component over which options may be written and an additional small sub-component of international (non-Australian/New Zealand listed) stocks. The trading portfolio consist of securities that are held for short term trading only, including call option contracts written over securities that are held in the specific sub-component of the investment portfolio and on occasion put options, and is relatively small in size. Its investment sectors include banks, industrials, healthcare, and others.

Anteotech Ltd

ADO

AnteoTech Ltd. engages in the development, manufacturing, and distribution of life sciences, clinical diagnostics and bio-separations products and services. The company is headquartered in Eight Mile Plains, Queensland. The company went IPO on 2000-04-11. The principal activities of the Company consist of development and commercialization of nanotechnologies with surface management applications. The Company’s lead product, Anteo X, provides significant improvement in anode performance and the Company partners with global suppliers in lithium-ion battery manufacturing. Its clean energy technology (CET) technologies improve the energy densities, cycle life and cost- effectiveness of lithium-ion batteries. The firm has two programs underway: Anteo X, its binder additive and the High Silicon Anode technology. The Life Sciences division services the point-of-care and in vitro diagnostics markets from global diagnostics companies to technology developers. Its AnteoBind provides advantages in bioconjugation to rapidly speed up testing procedures and improve accuracy.